SL2

Dr. Sidong Huang and his collaborator, Dr. Martin Schmeing, from the Rosalind and Morris Goodman Cancer Research Centre have uncovered synthetic lethal targets in various cancers. Focusing on the SWI/SNF chromatin remodeling complex, the team identified SL2, an exciting and novel mitochondrial target to treat certain intractable SMARCA4-deficient cancers. The project is currently focused on the identification of small molecules to treat small cell carcinoma of the ovary, hypercalcemic type (“SCCOHT”), an aggressive, rare form of ovarian cancer which affects predominantly women in their 20s. These inhibitors may also have the potential to treat other oncology indications, such as non-small cell lung cancer.